Silas Inman

CD19-direct CAR T-cell therapies and the CD20-targeted bispecific antibodies both represent a viable treatment choice for patents with relapsed/refractory follicular lymphoma.

Results from 2 studies shows ciltacabtagene autoleucel to prolong progression-free survival and induce response in patients with relapsed or refractory multiple myeloma.

There are several options the frontline setting for patients with chronic phase CML, with major randomized phase 3 trials showing long-term results for second-generation tyrosine kinase inhibitors.

Currently, CT/PET scans are primarily used for staging, response assessment, and surveillance, but these modalities have several limitations.

Results from the COMMANDS trial led the FDA to approve luspatercept for the treatment of anemia without prior erythropoiesis-stimulating agent use in adult patients with very low- to intermediate-risk MDS who may require regular red blood cell transfusions.

Patients with non–small cell lung cancer who completed definitive surgery saw clinical benefits after being treated with neoadjuvant nivolumab and chemotherapy.

Preliminary results from the phase 1/2 ARTEMIDE-01 trial show the potential for PD-1 and TIGIT bispecific agent rilvegostomig in patients with advanced or metastatic PD-L1–positive non–small cell lung cancer.

The results of vorasidenib signal potential for the agent to become the first targeted therapy in low-grade glioma.

MD Anderson Cancer Center's Hans C. Lee, MD has presented promising results from the phase 2 LINKER-MM1 study at ASCO.

The first study of a dual bispecific combination in relapsed or refractory multiple myeloma encourages the investigators.

News from KEYNOTE-671 in early-stage non–small cell lung cancer provides more evidence to support the FDA approval application for perioperative pembrolizumab.

The PARP inhibitor rucaparib bested physician’s choice of therapy for men with BRCA-altered metastatic castration-resistant prostate cancer in the phase 3 TRITON3 study.

Sacituzumab govitecan-hziy demonstrated a promising objective response rate in platinum-ineligible patients with metastatic urothelial cancer after progression on an immune checkpoint inhibitor.

Findings from the phase 2 HCRN GU 16-257 trial may help advance a more personalized approach to the management of muscle-invasive bladder cancer.

Phase 3 ALPINE study study results shows that zanubrutinib produced superior progression-free survival results and objective response rate compared with ibrutinib in chronic lymphoma leukemia and small lymphocytic lymphoma.

In the phase 3 TRANSFORM study, lisocabtagene maraleucel bested standard of care as treatment of patients with high-risk relapsed/refractory large B-cell lymphoma.

Phase 3 TRIANGLE results show the efficacy of ibrutinib induction and ibrutinib maintenance in patients with mantle cell lymphoma.

Phase 1/2 BRUIN study results show high response rates in patients with Waldenström macroglobulinemia who were treated with pirtobrutinib.

Positive results were reported on the phase 2 MagnetisMM-3 study at the ASH Annual Meeting 2022.

Significant improvements in progression-free survival were seen with sotorasib compared with docetaxel in patients with KRAS G12C–mutated non–small cell lung cancer.

Even after additional follow-up, the CLEAR trial showed a benefit for the combination of lenvatinib and pembrolizumab over sunitinib in patients with advanced clear cell renal cell carcinoma.

Positive signals from a blood-based multi-cancer early detection test led to cancer diagnoses after the test indicated potential cancers in 1.4% of individuals from an otherwise healthy cohort of participants in the the prospective PATHFINDER study.

The oncolytic virus T-VEC showed consistent improvements at 5 years for patients with stage IIIB to IVM1a melanoma.

A novel tumor-infiltrating lymphocyte therapy showed a 50% reduction in the risk of death for patients with stage IIIC/IV unresectable, treatment-refractory melanoma.

Findings presented at ESMO 2022 show the survival benefits of camrelizumab plus rivoceranib in patients with unresectable HCC.

A case report for zenocutuzumab supports emerging evidence that NRG1 fusions are targetable driver mutations in metastatic breast cancer.

Rivoceranib showed promising responses in regard to objective response rate and disease control rate when used in patients with recurrent or metastatic adenoid cystic carcinoma.

According to Timothy J. Whelan, MD, FASCO, radiotherapy is an inconvenient treatment. It can last daily for up to 5 weeks and it is a costly therapy. Study results shows that is can safely be omitted in the treatment of some patients with luminal A breast cancers.

At the 2022 ASCO Annual meeting, trastuzumab dreuxtecan was found to be a superior standard of care therapy for patients with hER2-low, hormone-positive metastatic breast cancer.

Treatment with a Claudin18.2–specific chimeric antigen receptor T-cell therapy has demonstrated either a response or stable disease in patients with heavily pretreated advanced gastric and pancreatic adenocarcinoma.